Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 5;80(1):24-28.
doi: 10.1093/cid/ciae332.

Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia

Sunish Shah  1   2 , Ellen G Kline  3 , Ghady Haidar  3 , Kevin M Squires  3 , Jason M Pogue  4 , Erin K McCreary  3 , Justin Ludwig  5 , Lloyd G Clarke  1   2 , Madison Stellfox  3 , Daria Van Tyne  3 , Ryan K Shields  1   3
Affiliations

Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia

Sunish Shah et al. Clin Infect Dis. .

Abstract

Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs 10%; P = .002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.

Keywords: Pseudomonas; MDR; ceftazidime-avibactam; ceftolozane-tazobactam; resistance.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. E. K. M. has served on advisory boards for AbbVie, Merck, Basilea, Shionogi, Melinta, Ferring, Cidara, Entasis, LabSimply, Pfizer, and GSK, and received a speaker honorarium from GSK, Shionogi, and Pfizer. J. M. P. has served as a consultant for AbbVie, GlaxoSmithKline, Merck, and Shionogi. He has received investigator-initiated funding from Merck. R. K. S. has served as a consultant for Allergan, Cidara, Shionogi, Menarini, Melinta, Merck, Entasis, Utility, and Venatorx, and has received investigator-initiated funding from Merck, Melinta, Shionogi, and Venatorx. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. Babiker A, Clarke LG, Saul M, et al. Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria, 2000–2017. Clin Infect Dis 2021; 73:e4521–30. - PMC - PubMed
    1. Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States 2019. 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re.... Accessed 10 January 2024.
    1. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 2022; 75:187–212. - PMC - PubMed
    1. Almangour TA, Ghonem L, Alassiri D, et al. Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study. Antimicrob Agents Chemother 2023; 67:e0040523. - PMC - PubMed
    1. Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 2017; 65:110–20. - PMC - PubMed

Publication types

MeSH terms